Yahoo Finance

Ring Therapeutics® Presents its Vector Conjugate and VectorBricks™ Manufacturing Platforms at the 29th Annual American Society of Gene & Cell Therapy Conference

CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- Ring Therapeutics®, a life sciences company pioneering a new class of targeted medicines, today announced new data on its Vector Conjugate platform and ...
Nature

Retrovirus molecular conjugates: a versatile and efficient gene transfer vector system for primitive human hematopoietic progenitor cells

In principle, transient nongenetic modification of a noninfectious gene transfer virus enabling a one time infection and transduction of human cells could eliminate the risk of formation of ...
Mena FN

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

(MENAFN- PR Newswire) PARIS, July 21, 2021 /PRNewswire/ -- Coave Therapeutics (pronounced 'cove'; formerly Horama), a clinical stage biotechnology company focused on developing life changing gene ...
technologynetworks

Lonza Expands Service Offerings for Early Phase Biopharmaceutical Drug Development

Expression systems are prone to generate protein sequence variants, which may lead to adverse events in patients. Typically, variant analysis is performed in Phase II/III. Finding variants at an ...
Morningstar%2c Inc.

Ring Therapeutics® Presents its Vector Conjugate and VectorBricks™ Manufacturing Platforms at the 29th Annual American Society of Gene & Cell Therapy Conference

With VectorBricks, Ring is able to make vectors and vector conjugates at greater cost efficiency and scale than existing technologies. "Ring's Vector Conjugate platform delivers orders of magnitude ...